Predictive Technology Group EBITDA
The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Predictive Technology Group (PREDQ) as of Jul 23, 2026 is -35.86 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -10.79 M USD — a change of 232.36% (lower).
Get this data via API
Financial Data API
EBITDA
-35.86 MUSD
YoY
232.36%
Last updated:
EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Predictive Technology Group is 2026 -35.86 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Predictive Technology Group was 2025 -10.79 M USD. It decreases by 232.36% lower compared to the previous year.
Access this data via the Eulerpool API
Predictive Technology Group Stock analysis
What does Predictive Technology Group do? Predictive Technology Group Inc is an American company specializing in the development, manufacturing, and marketing of diagnostic and therapeutic products in the field of gynecological health. The company was founded in 2015 in Salt Lake City, Utah, by successful entrepreneur Bradley Robinson.
The business model of Predictive Technology Group Inc is based on the use of state-of-the-art technologies and innovative methods to improve women's health while reducing healthcare costs. The company aims to bring groundbreaking products to the market that contribute to the prevention, diagnosis, and treatment of gynecological diseases.
Predictive Technology Group Inc has divided itself into various divisions to offer a wide range of products and services as well as consulting services. The company relies on the experience and expertise of specialists from different fields.
Among other things, the company specializes in the development of tests for hereditary breast and ovarian cancer risks. Advanced methods such as Next-Generation Sequencing are used to achieve higher precision and reliability in the identification of gene mutations.
Another important business area of Predictive Technology is laboratory services in the field of gynecological oncology. The company offers services such as the determination of tumor biomarkers, identification of gene mutations, and analysis of tissue samples.
Additionally, the company has developed a range of products to support assisted reproduction. These include innovative devices and procedures for improving sperm quality, stimulating egg maturation, and monitoring the artificial fertilization process.
To better meet the individual needs of patients, the company also focuses on the development of personalized medications. Information from the genome and other diagnostic tests is used to determine the optimal treatment for each patient.
To bring products and services to the market more quickly and effectively, the company also has its own research and development department. Highly qualified experts from various fields of medicine and science work together here to create new innovative solutions in the field of gynecological health.
Today, Predictive Technology Group Inc is a leading provider of diagnostic and therapeutic products in the field of gynecological health. The company relies on state-of-the-art technology and innovative methods to improve women's health worldwide. With a wide range of products and services, as well as its own research and development facility, Predictive Technology Group Inc remains an innovative pioneer in this important field of medicine. Predictive Technology Group is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Predictive Technology Group stock
EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Predictive Technology Group is -35.86 M USD in 2026.
Access this data via the Eulerpool API
Income Statement — Predictive Technology Group
All Key Metrics — Predictive Technology Group
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth